The Weed That Outperforms Most Greens: Omega-3s, Antioxidants, and Blood Sugar

Evidence Review

Omega-3 fatty acid content (Analysis, 1992 — PMID 1354675)

Simopoulos et al. conducted one of the first systematic analyses of purslane's nutritional composition in the United States, measuring fatty acid content, antioxidants, and micronutrients. The key finding was that purslane contained alpha-linolenic acid at ~400 mg/100 g fresh weight, making it the richest known leafy plant source of this essential fatty acid. The authors also detected small but measurable amounts of EPA (eicosapentaenoic acid), which was remarkable for a land plant and had not been previously described in leafy vegetables. Vitamin E (primarily alpha-tocopherol) measured approximately 12.2 mg/100 g — among the highest for any vegetable — and vitamin C was approximately 26 mg/100 g. The paper helped establish purslane as a nutritionally significant food that had been largely ignored in Western food culture. Limitations: this was an analytical chemistry study, not a clinical trial — it describes what purslane contains, not clinical outcomes.

Comprehensive nutritional review (Review, 2014 — PMID 24683365)

Uddin et al. synthesized the available literature on Portulaca oleracea's nutritional composition and health properties up to 2014. The review confirmed and extended Simopoulos's findings: ALA content varies by growth conditions (sunlight, water stress, and soil composition all affect it) but consistently ranges from 300–450 mg/100 g fresh weight. Betalain pigments — including betacyanins and betaxanthins — were identified as major antioxidant contributors, with activity documented in both in vitro and in some in vivo animal models. The review also noted: purslane contains calcium at approximately 65 mg/100 g; potassium at ~494 mg/100 g (notably high); and magnesium at ~68 mg/100 g. The mucilage content (polysaccharides in the cell walls) likely contributes to the blood sugar effects observed in clinical trials by slowing gastric emptying and glucose absorption. This review provides the mechanistic scaffolding for interpreting the clinical trial results.

Diabetes clinical trial (Double-blind RCT, 2016 — PMID 26854844)

Wainstein et al. conducted a 12-week, double-blind, placebo-controlled trial in adults with type 2 diabetes (n = 66 completers) to evaluate a standardized purslane extract. The supplement group received the extract alongside standard diabetes care; the control group received placebo plus standard care. Primary outcomes were fasting blood glucose and HbA1c. Results: the purslane group showed statistically significant reductions in both fasting blood glucose (mean reduction ~12 mg/dL, P < .05) and HbA1c (~0.4% reduction, P < .05) compared to placebo. Insulin resistance scores improved in the supplement group but not placebo. Notably, the extract was standardized and commercially produced, which improves reproducibility but means results may not directly translate to eating fresh purslane. No serious adverse events were reported. This is a well-designed trial for a botanical intervention: properly blinded, controlled against standard care, and with clinically meaningful primary endpoints.

Purslane seeds and glycemia (Crossover RCT, 2015 — PMID 25767522)

Esmaillzadeh et al. used a randomized, double-blind, placebo-controlled crossover design to test purslane seeds in 30 adults with type 2 diabetes. Each participant received purslane seeds or placebo for 8 weeks, crossed over with a 4-week washout period. This design eliminates between-person variability and is well-suited to detecting metabolic effects. Results: purslane seed consumption significantly reduced fasting blood glucose (mean difference approximately -10 mg/dL versus placebo), postprandial blood glucose, and LDL cholesterol. There were no statistically significant changes in HDL, triglycerides, or body weight. The LDL reduction is notable and may reflect the omega-3 and fiber content of the seeds. Limitations include small sample size and an Iranian university hospital setting that may limit generalizability. The crossover design is a strength — each participant's own baseline serves as their control.

Rheumatoid arthritis RCT (Parallel-arm RCT, 2024 — PMID 39306881)

Karimi et al. conducted an 8-week, parallel-arm, double-blind RCT in 60 patients with confirmed rheumatoid arthritis (RA) randomized to purslane supplementation or placebo alongside standard RA treatment. This is the most rigorous clinical trial of purslane's anti-inflammatory effects to date. Primary outcomes included DAS28 (disease activity score), inflammatory markers (CRP, IL-6, TNF-alpha), and antioxidant markers (total antioxidant capacity, superoxide dismutase, catalase). Results: the purslane group showed statistically significant reductions in DAS28 score (clinical disease activity), CRP, IL-6, and TNF-alpha compared to placebo (all P < .05). Total antioxidant capacity increased significantly versus placebo. These are clinically meaningful findings in an active inflammatory disease — RA involves persistent joint inflammation and oxidative stress, so improvements in this population suggest real-world relevance of the anti-inflammatory mechanisms. Limitations: RA patients are a specific population; effects in healthy adults or other inflammatory conditions may differ. The study is recent and should be replicated.

Overall evidence assessment

The nutritional evidence for purslane is strong and uncontroversial — it is genuinely one of the richest plant sources of ALA omega-3s and a broad-spectrum antioxidant food. The clinical evidence for blood sugar benefit is moderate-strength: two reasonably well-designed RCTs in diabetic populations both showed meaningful glycemic improvements. The anti-inflammatory evidence is early-stage but compelling, particularly the 2024 RA trial. This is not a well-known supplement category with decades of meta-analyses; the human trial literature is still relatively thin. What exists is promising and consistent with the biochemical profile of the plant. Purslane as a food carries no meaningful risks and substantial nutritional upside — the cost-benefit of adding it to a diet is very favorable even without waiting for further trials.